UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 100

Sortiert nach

EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer

Annals of oncology, 2019-08, Vol.30 (8), p.1311-1320

2019

Link zum Volltext

Verfügbarkeit prüfen

A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer

European journal of cancer (1990), 2015-11, Vol.51 (16), p.2321-2329

2015

Link zum Volltext

Verfügbarkeit prüfen

Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial

Annals of oncology, 2019-02, Vol.30 (2), p.281-289

2019

Link zum Volltext

Verfügbarkeit prüfen

A phase II study (ARCHER 1042) to evaluate prophylactic treatment of dacomitinib-induced dermatologic and gastrointestinal adverse events in advanced non-small-cell lung cancer

Annals of oncology, 2016-09, Vol.27 (9), p.1712-1718

2016

Link zum Volltext

Verfügbarkeit prüfen

IA18 A New World for Lung Cancer Vaccines: Beyond Picking a Single Antigen for Everyone

Journal of thoracic oncology, 2020-02, Vol.15 (2), p.S6-S6

Garon, E.B.

2020

Link zum Volltext

Verfügbarkeit prüfen

FP13.02 Pembrolizumab + Pemetrexed-Platinum vs Pemetrexed-Platinum for Metastatic NSCLC: 4-Year Follow-up From KEYNOTE-189

Journal of thoracic oncology, 2021-03, Vol.16 (3), p.S224-S224

2021

Link zum Volltext

Verfügbarkeit prüfen

Pembrolizumab (pembro) vs docetaxel (doce) for previously treated, PD-L1–expressing NSCLC: Updated outcomes of KEYNOTE-010

Annals of oncology, 2016-10, Vol.27, p.vi583-vi583

2016

Link zum Volltext

Verfügbarkeit prüfen

498 CDK4/6 inhibitor (LY2835219) exhibits potent anti-tumor activity in human lung cancer cell lines with intact retinoblastoma

European journal of cancer (1990), 2014-11, Vol.50, p.162-162

2014

Link zum Volltext

Verfügbarkeit prüfen

3089 Symptom analysis and quality of life (QoL) in patients treated with nivolumab (NIVO) as ≥2nd line therapy for advanced non-small cell lung cancer (aNSCLC)

European journal of cancer (1990), 2015-09, Vol.51, p.S628-S629

2015

Link zum Volltext

Verfügbarkeit prüfen

33LBA Efficacy and Safety of Pembrolizumab (Pembro; MK-3475) for Patients (Pts) With Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) Enrolled in KEYNOTE-001

European journal of cancer (1990), 2015-09, Vol.51, p.S726-S727

2015

Link zum Volltext

Verfügbarkeit prüfen

3073 Exploratory analysis of frontline therapies in REVEL: A randomized phase III study of ramucirumab (RAM) plus docetaxel (DOC) versus DOC for the treatment of stage IV non-small-cell lung cancer (NSCLC) after disease progression on platinum-based therapy

European journal of cancer (1990), 2015-09, Vol.51, p.S621-S621

2015

Link zum Volltext

Verfügbarkeit prüfen

Early Outcomes from a Prospective Phase II Trial Evaluating Safety and Efficacy of Combining SBRT with RFA for Centrally Located Lung Tumors

International journal of radiation oncology, biology, physics, 2014-09, Vol.90 (1), p.S29-S29

2014

Link zum Volltext

Verfügbarkeit prüfen

Safety and Clinical Activity of MK-3475 as Initial Therapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

International journal of radiation oncology, biology, physics, 2014-11, Vol.90 (5), p.S1-S2

2014

Link zum Volltext

Verfügbarkeit prüfen

Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189

Annals of oncology, 2021-07, Vol.32 (7), p.881-895

2021

Link zum Volltext

Verfügbarkeit prüfen

Phase I Trial of Trans-thoracic Injection of CCL21 Gene Modified Dendritic Cells in Human Non-small Cell Lung Carcinoma

The Journal of surgical research, 2014-02, Vol.186 (2), p.558-558

2014

Link zum Volltext

Verfügbarkeit prüfen

Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial

Annals of oncology, 2017-04, Vol.28 (4), p.874-881

2017

Link zum Volltext

Verfügbarkeit prüfen

1529MO The genomic landscape of small cell lung cancer in never smoking patients

Annals of oncology, 2022-09, Vol.33, p.S1245

2022

Link zum Volltext

Verfügbarkeit prüfen

Rociletinib in EGFR-Mutated Non–Small-Cell Lung Cancer

The New England journal of medicine, 2015-04, Vol.372 (18), p.1700-1709

2015

Link zum Volltext

Verfügbarkeit prüfen

Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab

Annals of oncology, 2017-12, Vol.28 (12), p.2932-2942

2017

Link zum Volltext

Verfügbarkeit prüfen

Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer

Annals of oncology, 2016-07, Vol.27 (7), p.1291-1298

2016

Link zum Volltext

Verfügbarkeit prüfen

P2.06-05 Durvalumab ± Tremelimumab + Chemotherapy in 1L Metastatic NSCLC: Characterisation of patients with PFS ≥12 months in POSEIDON

Journal of thoracic oncology, 2023-11, Vol.18 (11), p.S318-S319

2023

Link zum Volltext

Verfügbarkeit prüfen

986P Response to capmatinib in patients (pts) with advanced non-small cell lung cancer (NSCLC) and MET exon 14 skipping (METex14) mutation: Whole transcriptome analysis from phase II GEOMETRY Mono-1 study

Annals of oncology, 2022-09, Vol.33, p.S1003

2022

Link zum Volltext

Verfügbarkeit prüfen

26P Capmatinib in treatment (Tx)-naive MET exon 14-mutated (METex14) advanced non-small cell lung Cancer (aNSCLC): Updated results from GEOMETRY mono-1

Annals of oncology, 2022-04, Vol.33, p.S42

2022

Link zum Volltext

Verfügbarkeit prüfen

A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer

Annals of oncology, 2012-11, Vol.23 (11), p.2834-2842

2012

Link zum Volltext

Verfügbarkeit prüfen

1209P RELAY, ramucirumab plus erlotinib (RAM+ERL) in untreated metastatic EGFR-mutant NSCLC (EGFR+NSCLC): Association between TP53 status and clinical outcome

Annals of oncology, 2021-09, Vol.32, p.S962-S963

2021

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 100

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(100)
Mit Volltextzugriff
(98)

Publikationsform

Artikel
(100)

Sprache

Erscheinungsjahr

n.n

Kollektion

Free E-Journal (出版社公開部分のみ）
(88)
Journals@Ovid Complete
(84)
Ingenta
(17)
Elsevier ScienceDirect Journals Complete
(13)
MEDLINE
(11)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(10)
IngentaConnect Journals
(8)
NUS Single-Journal Subscriptions
(1)

3 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer

A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer

Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial

A phase II study (ARCHER 1042) to evaluate prophylactic treatment of dacomitinib-induced dermatologic and gastrointestinal adverse events in advanced non-small-cell lung cancer

IA18 A New World for Lung Cancer Vaccines: Beyond Picking a Single Antigen for Everyone

FP13.02 Pembrolizumab + Pemetrexed-Platinum vs Pemetrexed-Platinum for Metastatic NSCLC: 4-Year Follow-up From KEYNOTE-189

Pembrolizumab (pembro) vs docetaxel (doce) for previously treated, PD-L1–expressing NSCLC: Updated outcomes of KEYNOTE-010

498 CDK4/6 inhibitor (LY2835219) exhibits potent anti-tumor activity in human lung cancer cell lines with intact retinoblastoma

3089 Symptom analysis and quality of life (QoL) in patients treated with nivolumab (NIVO) as ≥2nd line therapy for advanced non-small cell lung cancer (aNSCLC)

33LBA Efficacy and Safety of Pembrolizumab (Pembro; MK-3475) for Patients (Pts) With Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) Enrolled in KEYNOTE-001

3073 Exploratory analysis of frontline therapies in REVEL: A randomized phase III study of ramucirumab (RAM) plus docetaxel (DOC) versus DOC for the treatment of stage IV non-small-cell lung cancer (NSCLC) after disease progression on platinum-based therapy

Early Outcomes from a Prospective Phase II Trial Evaluating Safety and Efficacy of Combining SBRT with RFA for Centrally Located Lung Tumors

Safety and Clinical Activity of MK-3475 as Initial Therapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189

Phase I Trial of Trans-thoracic Injection of CCL21 Gene Modified Dendritic Cells in Human Non-small Cell Lung Carcinoma

Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial

1529MO The genomic landscape of small cell lung cancer in never smoking patients

Rociletinib in EGFR-Mutated Non–Small-Cell Lung Cancer

Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab

Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer

P2.06-05 Durvalumab ± Tremelimumab + Chemotherapy in 1L Metastatic NSCLC: Characterisation of patients with PFS ≥12 months in POSEIDON

986P Response to capmatinib in patients (pts) with advanced non-small cell lung cancer (NSCLC) and MET exon 14 skipping (METex14) mutation: Whole transcriptome analysis from phase II GEOMETRY Mono-1 study

26P Capmatinib in treatment (Tx)-naive MET exon 14-mutated (METex14) advanced non-small cell lung Cancer (aNSCLC): Updated results from GEOMETRY mono-1

A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer

1209P RELAY, ramucirumab plus erlotinib (RAM+ERL) in untreated metastatic EGFR-mutant NSCLC (EGFR+NSCLC): Association between TP53 status and clinical outcome

Suchergebnisse filtern